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Abstract
Contradictory statements about the non-steroidal anti-inflammatory drugs from the European
Medicines Agency and the United States Food and Drug Administration have raised questions
about whether regulatory decisions are evidence-based. For the selective COX-2 inhibitors, there
are clear contraindications and warnings in Europe, but only a vaguely worded Black Box warning
in the United States. All the non-selective agents are given an almost "clean bill of health" in Europe,
while all of them are judged to have a similar risk-benefit ratio as celecoxib in the United States.
The regulatory agencies have failed to recognize the clinical trial evidence that the risk of
cardiovascular events varies substantially among the non-selective agents, with diclofenac carrying
the highest risk of harm.
Background
Decisions by regulatory agencies follow explicit regula-
tions and should be evidence-based. An established prac-
tice has been that approval of a new drug requires two
independent clinical trials documenting safety and effi-
cacy for the drug's intended use. But are the regulatory
agencies rigorously ensuring that decisions are evidence-
based? Contradictory statements about the non-steroidal
anti-inflammatory drugs (NSAIDs) from the European
Medicines Agency (EMEA) and the U.S. Food and Drug
Administration (FDA) have raised this question.
Discussion
Selective COX-2 inhibitors
An FDA Advisory Committee convened in February, 2005
to review primarily the three selective COX-2 inhibitors
available in the U.S. It concluded overwhelmingly (32
votes to zero) that these agents increase the risk of throm-
botic cardiovascular events[1]. The evidence from several
placebo-controlled clinical trials was considered conclu-
sive. The problem was interpreted as a class effect,
although the degree of harm appeared to differ among the
agents. The Advisory Committee recommended that
celecoxib remain on the market with major restrictions
applied to its use[1].
EMEA was in agreement with the FDA and recommended
suspension of valdecoxib[2]. It also added new contrain-
dications and warnings to the other marketed coxibs.
Contraindications were added for patients with estab-
lished ischemic vascular disease and reinforced warnings
were issued for patients with risk factors of heart disease.
Based on the same available scientific evidence, the FDA
did not follow the recommendations by its Advisory
Committee[3]. Rather the FDA added only a Black Box
warning vaguely stating that celecoxib "may (author's
emphasis) cause an increased risk of serious cardiovascu-
lar events,..." and that "Patients with cardiovascular dis-
ease or risk factors for cardiovascular disease may
(author's emphasis) be at greater risk"[4].
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The recommendations for the non-selective NSAIDs by
FDA and EMEA issued in 2006 also went in a different
direction. EMEA concluded that the risk-benefit balance
for eleven of these agents remains favorable[5]. However,
it could not exclude "a small increase in risk of thrombotic
events." FDA added to the Black Box warning for celecoxib
that "All NSAIDs may (author's emphasis) have a similar
risk. This risk may (author's emphasis) increase with dura-
tion of use"[4]. Again, the different conclusions by the
regulatory agencies were based on the same available sci-
entific evidence.
So what is the evidence for cardiotoxic effects of non-
selective NSAIDs? The safety information is limited, with
no large, long-term, placebo-controlled trials. In their
meta-analysis, Kearney et al.[6] reported summary rate
ratios for high doses of naproxen, ibuprofen and
diclofenac in comparison with placebo; these ratios were
0.92 (95% CI 0.67 to1.26), 1.51 (0.96 to 2.37) and 1.63
(1.12 to 2.37), respectively. The authors concluded "Our
results indicated that high-dose ibuprofen (800 mg three
times daily) and high-dose diclofenac (75 mg twice daily)
were each associated with an increased risk of vascular
events, but that the risks of high-dose naproxen (500 mg
twice daily) were substantially smaller."
A recent indirect comparison supports these findings[7].
In 26 active-control trials comparing COX-2 inhibitors to
diclofenac, the risk of vascular events was lower with the
COX-2 inhibitors (relative risk 0.92; 95% CI, 0.81–1.05).
For trials comparing COX-2 inhibitors to naproxen, the
former were associated with an increased vascular risk
(relative risk 1.57; 95% CI, 1.21 to 2.03). Thus, compared
to naproxen, diclofenac may increase the vascular risk by
about 70%[7].
The scientific evidence points to major differences among
the non-selective NSAIDs. Naproxen appears to be fairly
neutral in its cardiovascular effects. In fact, at the FDA
Hearing in February 2005, the Advisory Committee rec-
ommended that naproxen be the preferred NSAID com-
parator in future trials of painkillers[1]. Diclofenac has
pharmacologic effects similar to those of celecoxib. The
evidence is fairly overwhelming that this drug increases
the risk of cardiovascular events. However, the regulatory
agencies so far have not recognized these clinically impor-
tant differences among the non-selective NSAIDs. Since
diclofenac is the most commonly used non-selective
NSAID and since it increases the risk of vascular events by
60–70%, the unrecognized harm it has caused worldwide
could be enormous. Consideration ought to be given to
removing this drug from the market, since there is not evi-
dence that it offers better pain control than the large
number of non-selective NSAIDs on the market.
Conclusion
EMEA gave all non-selective NSAIDs an almost "clean bill
of health" while the FDA created an unnecessary "health"
scare among patients using these drugs by suggesting that
all of them have vascular risks similar to celecoxib. Both
positions are partially right according to the scientific evi-
dence, since some non-selective NSAIDs increase risk of
cardiovascular events, while others do not. Being half-
right is not good enough. The time has come for EMEA
and FDA to set the record straight, based on current scien-
tific evidence.
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